Repurposing therapeutic drugs complexed to Vanadium in Cancer

De Sousa-Coelho, Ana Luísa; Fraqueza, Gil; Aureliano, M.

http://hdl.handle.net/10400.1/20323

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
pharmaceuticals-17-00012.pdf		1.71 MB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

De Sousa-Coelho, Ana Luísa

Fraqueza, Gil

Aureliano, M.

Resumo(s)

Repurposing drugs by uncovering new indications for approved drugs accelerates the process of establishing new treatments and reduces the high costs of drug discovery and development. Metal complexes with clinically approved drugs allow further opportunities in cancer therapy—many vanadium compounds have previously shown antitumor effects, which makes vanadium a suitable metal to complex with therapeutic drugs, potentially improving their efficacy in cancer treatment. In this review, covering the last 25 years of research in the field, we identified non-oncology-approved drugs suitable as ligands to obtain different vanadium complexes. Metformin-decavanadate, vanadium-bisphosphonates, vanadyl(IV) complexes with non-steroidal anti-inflammatory drugs, and cetirizine and imidazole-based oxidovanadium(IV) complexes, each has a parent drug known to have different medicinal properties and therapeutic indications, and all showed potential as novel anticancer treatments. Nevertheless, the precise mechanisms of action for these vanadium compounds against cancer are still not fully understood.